The Global Sclerotherapy Market size is expected to reach $1.2 billion by 2026, rising at a market growth of 7.9% CAGR during the forecast period. Sclerotherapy is a less invasive treatment that are used in treatment of varicose veins. The procedure involves the injection of a sclerosing agent’s solution directly into the affected veins, resulting in their shrink and they eventually get disappeared. It is medical procedure that are useful for the treatment of blood vessel and lymphatic system malformations.
The sclerotherapy is usually used to treat spider veins, haemorrhoids, and smaller varicose veins in adults. In Sclerotherapy, a very fine and thin injection needle is used to inject solution in order to treat small varicose veins in the legs, improve the appearance of spider veins, and get rid of related symptoms like burning, aching, swelling and cramping. Dermatologists have played an important role in the advancement of new safe, and non-invasive technologies that can be use in the treatment of both larger varicose veins, and cosmetic telangiectasias and procedure has become a medical significance. The major advancements have been made in sclerosing solutions, and endovascular RF and laser procedures and they have brought a revolution in the healthcare industry.
In the current scenario, more respected hospital is preferring to opt for minimally invasive surgical procedure including Sclerotherapy Treatment. Sclerosing agents that are used for the varicose veins treatment is segmented into detergents, chemical irritants, and hyperosmolar/ osmotic agents. Agents such as Sodium morrhuate (Scleromate), Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Ethanolamine Oleate (Ethamoline) are approved by FDA therefore these sclerosants are used to treat and decrease the effect of vein damage. As per the Society of Vascular surgery, around 33.0% of women and more than 17.0% of men refer a doctor for varicose veins, and telangiectasias in developed countries, that has affected up to 35.0% of people in the U.S.
| Report Attribute | Details |
|---|---|
| Market size value in 2019 | USD 812.3 Million |
| Market size forecast in 2026 | USD 1.2 Billion |
| Base Year | 2019 |
| Historical Period | 2016 to 2018 |
| Forecast Period | 2020 to 2026 |
| Revenue Growth Rate | CAGR of 7.9% from 2020 to 2026 |
| Number of Pages | 132 |
| Number of Tables | 260 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Agent, Type, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Free Valuable Insights: Global Sclerotherapy Market to reach a market size of $1.2 billion by 2026
Based on Agent, the market is segmented into Detergents, Osmotic Agents and Chemical Irritants. Based on Type, the market is segmented into Liquid Sclerotherapy, Ultrasound Sclerotherapy and Foam Sclerotherapy. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Perrigo Company PLC (Omega Pharmaceuticals), Cook Medical, Inc. (Cook Group), Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, LLC, Troikaa Pharmaceuticals Limited, Tianyu Chang’an Group, Endo-Flex GmbH (Meditek Systems), Merz Pharma GmbH & Co. KGaA, and MTW-Endoskopie W. Haag KG.
Market Segmentation:
By Agent
By Type
By Geography
Companies Profiled
The global sclerotherapy market size is expected to reach $1.2 Million by 2026.
Boston Scientific Corporation, Perrigo Company PLC (Omega Pharmaceuticals), Cook Medical, Inc. (Cook Group), Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, LLC, Troikaa Pharmaceuticals Limited, Tianyu Chang’an Group, Endo-Flex GmbH (Meditek Systems), Merz Pharma GmbH & Co. KGaA, and MTW-Endoskopie W. Haag KG.
The expected CAGR of the sclerotherapy market is 7.9% from 2020 to 2026.
The detergents segment has the largest market share in the year 2019 and is anticipated to reciprocate the prominent CAGR in the coming years.
Increase of technological advancements pertaining to venous diseases and cardiology are driving the market in coming years, however, side effects and risks associated with sclerotherapy treatment have limited the growth of the market.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
